• Aktuelle Seite:  
  • Home
  • NAS - Neonatales Abstinenzsyndrom
A- A A+

USA. National Perinatal Association: Perinatal Substance Use

Themenseite. (aufgerufen zuletzt am 19.05.2023)

https://www.nationalperinatal.org/resources

New study identifies a more effective way to care for newborns exposed to opioids

Findings from the Eating, Sleeping and Consoling for Neonatal Opioid Withdrawal (ESC-NOW) study show a new care approach that is more effective than usual care approaches for opioid-exposed infants. 

Eat, Sleep, Console promotes parental engagement and gives special attention to non-medication care methods like breastfeeding, swaddling, and skin-to-skin contact. The usual treatment for NOWS focuses on a nurse measuring the infant's withdrawal symptoms before providing medication treatment, such as methadone or morphine.

Researchers found that the ESC approach decreased the time until infants were medically ready for discharge. Newborns cared for with ESC were medically ready for discharge approximately 6.7 days earlier and were 63% less likely to receive drug therapy, compared to newborns cared for under the usual approach using traditional scoring methods. Safety outcomes at three months of age were similar between both groups. The study appears in the New England Journal of Medicine.

The nationwide clinical trial is a collaborative effort between NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the NIH Environmental Influences on Child Health Outcomes (ECHO) Program. The trial is funded by the Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative®—a trans-agency effort to speed scientific solutions to stem the national opioid crisis. (Addiction Policy Forum, USA, 08.05.2023)

https://www.addictionpolicy.org/post/new-study-identifies-a-more-effective-way-to-care-for-newborns-exposed-to-opioids

Maternal opioids age-dependently impair neonatal respiratory control networks. 

Beyeler SA, Naidoo R, Morrison NR, McDonald EA, Albarrán D, Huxtable AG. 

Front Physiol. 2023 Mar 16;14:1109754. doi: 10.3389/fphys.2023.1109754. PMID: 37008014; PMCID: PMC10060555.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10060555/

Disparity in neonatal abstinence syndrome by race/ethnicity, socioeconomic status, and geography, in neonates ≥ 35 weeks gestational age. 

Dookeran KA, Feffer MG, Quigley KM, Troller PE, Christmon CA, Khan JY. 

PLoS One. 2023 Apr 5;18(4):e0284040. doi: 10.1371/journal.pone.0284040. PMID: 37018348; PMCID: PMC10075424.

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0284040

Executive functioning, behavioural, emotional, and cognitive difficulties in school-aged children prenatally exposed to methadone. 

Spowart KM, Reilly K, Mactier H, Hamilton R. 

Front Pediatr. 2023 Apr 18;11:1118634. doi: 10.3389/fped.2023.1118634. PMID: 37144152; PMCID: PMC10151701.

https://www.frontiersin.org/articles/10.3389/fped.2023.1118634/full

Effects of medications for opioid use disorder (MOUD) on fetal brain and cranial measurements. 

Chao CR, Perez Yordan J, Roberts M, Ma X, Holbrook B, Rayburn W, Bakhireva LN. 

Neurotoxicol Teratol. 2023 Apr 19;97:107177. doi: 10.1016/j.ntt.2023.107177. Epub ahead of print. PMID: 37084853.

https://www.sciencedirect.com/science/article/abs/pii/S0892036223000272

Eat, Sleep, Console Approach or Usual Care for Neonatal Opioid Withdrawal. 

Young LW, Ounpraseuth ST, Merhar SL, Hu Z, Simon AE, Bremer AA, Lee JY, Das A, Crawford MM, Greenberg RG, Smith PB, Poindexter BB, Higgins RD, Walsh MC, Rice W, Paul DA, Maxwell JR, Telang S, Fung CM, Wright T, Reynolds AM, Hahn DW, Ross J, McAllister JM, Crowley M, Shaikh SK, Puopolo KM, Christ L, Brown J, Riccio J, Wong Ramsey K, Akshatha, Braswell EF, Tucker L, McAlmon KR, Dummula K, Weiner J, White JR, Howell MP, Newman S, Snowden JN, Devlin LA; ACT NOW Collaborative. 

N Engl J Med. 2023 Apr 30. doi: 10.1056/NEJMoa2214470. Epub ahead of print. PMID: 37125831.

Abstract (zwei Artikel pro Monat frei)

https://www.nejm.org/doi/10.1056/NEJMoa2214470

„Eat, Sleep, Console“: Neuer Therapieansatz erleichtert neonatalen Opiatentzug

Burlington/Vermont – Das Konzept „Eat, Sleep, Console“, das die Diagnose eines neonatalen Entzugssyndroms erleichtert und in der Behandlung nicht-pharmakologische Pflegeansätze bevorzugt, hat in einer randomisier­ten Studie im New England Journal of Medicine(NEJM 2023; DOI: 10.1056/NEJMoa2214470) die Entlassung der Säuglinge aus der Klinik beschleunigt, ohne dass es in den ersten 3 Monaten zu häufigeren Notfallbe­hand­lungen oder anderen Komplikationen kam. (aerzteblatt.de, 05.05.2023)

https://www.aerzteblatt.de/nachrichten/142851/Eat-Sleep-Console-Neuer-Therapieansatz-erleichtert-neonatalen-Opiatentzug

Themenseite. Neonataler Drogenentzug

(…) Ein Konzept zum neonatalen Drogenentzug kann sich zwangsläufig nicht alleine mit Symptomen des Entzuges, Dosierung der Substitutionsmedikamente und der Abklärung somatischer Komplikationen der Drogenexposition beschäftigen, sondern muss konsequent im präventiven Bereich aktiv sein, d.h. gemeinsam mit den Streetworkern, Drogenambulanzen und Kontaktzentren Aufklärung betreiben und ansprechbar sein, die Mütter früh gynäkologisch und psychosozial durch ihre Schwangerschaft begleiten, Schwangere aus der Illegalität holen und ihnen die Angst vor den beteiligten Institutionen nehmen. Besonderheiten der Substitution während der Schwangerschaft müssen mit den substituierenden Ambulanzen und Praxen beraten werden. „Im Klartext“ muss die Anamnese erhoben werden; Ressourcen, Risiken, Chancen, Vorgaben und Ziele der Behandlung müssen besprochen und festgelegt werden. Zur Entlassung ist ein klar strukturiertes, personengebundenes, verantwortliches und dichtes Netzwerk für entwicklungsneurologische und psychosoziale Nachsorge, Förderung und Betreuung vorzuhalten. Das Wohl des Kindes, als höchstes Gut, darf bei allen Überlegungen nie aus den Augen verloren werden. (Universitätsklinikum Schleswig-Holstein, Campus Lübeck, aufgerufen am 06.05.2023)

https://www.uksh.de/paediatrie-luebeck/Patienten+und+Eltern/Patienten_+und+Elternschulungen/Neonataler+Drogenentzug.html

Perinatal Psychoactive Substances Use: A Rising Perinatal Mental Health Concern. 

ELNahas G, Thibaut F. 

Clin Med. 2023 Mar 10;12(6):2175. doi: 10.3390/jcm12062175. PMID: 36983176; PMCID: PMC10056692.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056692/

A review of the literature: How does prenatal opioid exposure impact placental health and fetal brain development? 

Humphries A, Simcox K, Howell B. 

Dev Psychobiol. 2023 Apr;65(3):e22378. doi: 10.1002/dev.22378. PMID: 36946682.

https://onlinelibrary.wiley.com/doi/10.1002/dev.22378

Ondansetron to reduce neonatal opioid withdrawal severity a randomized clinical trial. 

Peltz G, Jansson LM, Adeniyi-Jones S, Cohane C, Drover D, Shafer S, Wang M, Wu M, Govindaswami B, Jegatheesan P, Argani C, Khan S, Kraft WK. 

J Perinatol. 2023 Mar;43(3):271-276. doi: 10.1038/s41372-022-01487-2. Epub 2022 Aug 27. PMID: 36030327; PMCID: PMC9968817.

Abstract

https://www.nature.com/articles/s41372-022-01487-2

Evaluating a Web-based Training Curriculum for Disseminating Best Practices for the Care of Newborns with Neonatal Opioid Withdrawal Syndrome in a Rural Hospital, the NOWS-NM Program. 

Pratt-Chavez H, Brakey HR, Sanders SG, Patel J, Ozechowski T, Stoffel C, Sussman AL, Marquez J, Smith DR, Kong AS. 

Res Sq [Preprint]. 2023 Feb 16:rs.3.rs-2531394. doi: 10.21203/rs.3.rs-2531394/v1. PMID: 36824938; PMCID: PMC9949247.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949247/

Comparing maternal substance use and perinatal outcomes before and during the COVID-19 pandemic. 

Lien J, Hayes T, Liu-Smith F, Rana D. 

J Perinatol. 2023 Feb 6:1–6. doi: 10.1038/s41372-023-01613-8. Epub ahead of print. PMID: 36746986; PMCID: PMC9901406.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901406/

Effects of neonatal fentanyl on late adolescent opioid-mediated behavior. 

Crawford CA, Taylor JA, Park GI, Rios JW, Bunch J, Greenwood CJ, Lopez Sanchez DY, Gonzales DJ. 

Front Neurosci. 2023 Feb 14;17:1094241. doi: 10.3389/fnins.2023.1094241. PMID: 36866335; PMCID: PMC9971583.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971583/

Morbidity through 3 Years of Age in Children of Women Using Methamphetamine during Pregnancy: A National Registry Study. 

Gabrhelík R, Skurtveit S, Nechanská B, Mravčík V, Handal M. 

Eur Addict Res. 2023;29(1):19-29. doi: 10.1159/000527238. Epub 2022 Nov 24. PMID: 36423599; PMCID: PMC9932820.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932820/

Intrauterine and Neonatal Exposure to Opioids: Toxicological, Clinical, and Medico-Legal Issues. 

Albano GD, La Spina C, Pitingaro W, Milazzo V, Triolo V, Argo A, Malta G, Zerbo S. 

Toxics. 2023 Jan 9;11(1):62. doi: 10.3390/toxics11010062. PMID: 36668788; PMCID: PMC9866828.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866828/

A case-control study comparing rates and diagnoses of hospital readmission in infants affected by neonatal abstinence syndrome. 

Salt E, Wiggins A, Pick A, Bada H, Howard C, Currie M, Rayens MK. 

J Matern Fetal Neonatal Med. 2023 Dec;36(1):2162820. doi: 10.1080/14767058.2022.2162820. PMID: 36597833.

https://www.tandfonline.com/doi/full/10.1080/14767058.2022.2162820

Children born to women in opioid maintenance treatment: A longitudinal study of child behavioral problems and parenting stress. 

Sarfi M, Eikemo M, Konijnenberg C. 

Front Pediatr. 2022 Dec 23;10:1087956. doi: 10.3389/fped.2022.1087956. PMID: 36619511; PMCID: PMC9816796.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816796/

Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent Opioids. 

Ceccanti M, Blum K, Bowirrat A, Dennen CA, Braverman ER, Baron D, Mclaughlin T, Giordano J, Gupta A, Downs BW, Bagchi D, Barh D, Elman I, Thanos PK, Badgaiyan RD, Edwards D, Gold MS. 

J Pers Med. 2022 Dec 6;12(12):2015. doi: 10.3390/jpm12122015. PMID: 36556236; PMCID: PMC9782293.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782293/

Association of medication-assisted treatment and short acting opioids with newborn head circumference and birth weight. 

Cutler, A.J., Cox, D.F., Gabrielson, S.M.B. et al.

J Perinatol (2022). doi.org/10.1038/s41372-022-01579-z

Abstract

https://www.nature.com/articles/s41372-022-01579-z#citeas

Understanding the effects of opioids vs non-opioids in the treatment of neonatal abstinence syndrome, an in vitro model. 

Sithisarn T, Legan SJ, Westgate PM, Bada HS, Wilson ME. 

Front Pediatr. 2022 Nov 22;10:1068330. doi: 10.3389/fped.2022.1068330. PMID: 36483468; PMCID: PMC9723166.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723166/

Neonatal abstinence syndrome hospitalizations in Canada: a descriptive study. 

Plouffe R, Grywacheski V, Luo W, Nelson C, Orpana H. 

Can J Public Health. 2022 Dec 8:1–10. doi: 10.17269/s41997-022-00726-5. Epub ahead of print. PMID: 36482143; PMCID: PMC9734797.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9734797/

Behavioral Outcomes of Children With In-Utero Opioid Exposure Age 2-7 and Parenting Self-Efficacy. 

Arter S, Kiel E, McAllister J, Hay MC. 

J Am Psychiatr Nurses Assoc. 2022 Dec 7:10783903221139840. doi: 10.1177/10783903221139840. Epub ahead of print. PMID: 36475408.

https://journals.sagepub.com/doi/10.1177/10783903221139840

Quality Improvement Targeting Non-pharmacologic Care and As-needed Morphine Improves Outcomes in Neonatal Abstinence Syndrome. 

McMorrow TJ, Byrnes K, Gates M, Hairston T, Jawed A, Keydash M, Steele SU, Thorndike D, van Londen L, Bodnar BE. 

Pediatr Qual Saf. 2022 Nov 10;7(6):e612. doi: 10.1097/pq9.0000000000000612. PMID: 36382144; PMCID: PMC9649270.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649270/

A Preliminary Assessment of the Effects of Pharmacist-Driven Methadone Stewardship for the Treatment of Neonatal Abstinence Syndrome at a Tertiary Children's Hospital. 

Celestin G, Balding M, Para JL, Utley A, Shaddix BP. 

J Pediatr Pharmacol Ther. 2022;27(8):720-724. doi: 10.5863/1551-6776-27.8.720. Epub 2022 Nov 17. PMID: 36415769; PMCID: PMC9674361.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674361/

The immediate and long-term effects of prenatal opioid exposure. 

Yen E, Davis JM. 

Front Pediatr. 2022 Nov 7;10:1039055. doi: 10.3389/fped.2022.1039055. PMID: 36419918; PMCID: PMC9676971.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676971/

The effect of prenatal cannabis exposure on offspring preterm birth: a cumulative meta-analysis, 

Duko, B., Dachew, B. A., Pereira, G., and Alati, R. (2022) 

Addiction. doi.org/10.1111/add.16072

https://onlinelibrary.wiley.com/doi/epdf/10.1111/add.16072

Newborn Cry Acoustics in the Assessment of Neonatal Opioid Withdrawal Syndrome Using Machine Learning. 

Manigault AW, Sheinkopf SJ, Silverman HF, Lester BM. 

JAMA Netw Open. 2022 Oct 3;5(10):e2238783. doi: 10.1001/jamanetworkopen.2022.38783. PMID: 36301544.

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2797784

Neonatal outcomes of preterm infants with in-utero exposure to drugs of substance use: US national data. 

Puthuraya S, Karnati S, Othman H, Sripathi R, Nandakumar V, Aly H. 

Pediatr Neonatol. 2022 Sep 9:S1875-9572(22)00191-7. doi: 10.1016/j.pedneo.2022.03.021. Epub ahead of print. PMID: 36283910.

https://linkinghub.elsevier.com/retrieve/pii/S1875-9572(22)00191-7

  1. Comparison of neonatal outcomes in pregnant women undergoing medication-assisted treatment of opioid use disorder with methadone or buprenorphine/naloxone,
  2. One-Year Neurodevelopmental Outcomes After Neonatal Opioid Withdrawal Syndrome: A Prospective Cohort Study. 
  3. Addressing drivers of healthcare utilization for neonatal opioid withdrawal syndrome. 
  4. Fostering Hope: Comprehensive Accessible Mother-Infant Dyad Care for Neonatal Abstinence (CAIN). 
  5. Methamphetamine Use During the First or Second Half of Pregnancy Worsens Cardiac Ischemic Injury in Adult Female Offspring.